Iodine-131 5 mCi, tositumomab 35 mg IV over 20 minutes; Allows for individualized dosing. Nonradioactive tositumomab administered via IV injection followed by trace amount of radioactive I-131 to evaluate clearance of radiation from patient. Gamma scan is performed immediately following and at two and four days following dosimetric dose.

Uses for Bexxar Relapsed or Refractory CD20-Positive, Non-Hodgkin's Lymphoma. The BEXXAR® therapeutic regimen (tositumomab and iodine I 131 tositumomab) is indicated for the treatment of patients with CD20-positive relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma who have …

CASE 4: Patient diagnosed with Hodgkin's granuloma of intra-abdominal lymph nodes and spleen underwent outpatient radiopharmaceutical therapy via intravenous administration of therapeutic iodine I-131 tositumomab radiopharmaceutical therapy, one treatment dose. Which ICD-10-CM code is reported for the first-listed diagnosis? a. C81.73 b. C81.98

Tositumomab is an IgG2a murine anti-CD20 monoclonal antibody. 3 In vitro, the binding of tositumomab to CD20-positive cells invoked antibody-dependent cellular cytotoxicity, 11 complement-dependent cytotoxicity, 12 and apoptosis. 13 Conjugation of tositumomab to a radionuclide such as iodine 131 (131 I) affords irradiation of …

Iodine 131 tositumomab in the treatment of non-Hodgkin'slymphoma.FutureOncol2007;3:255–62 11. DosikAD,ColemanM,KostakogluL,etal.Subsequenttherapycanbeadmin-istered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer …

Tositumomab and iodine I 131 tositumomab (Bexxar® Therapeutic Regimen) has been found effective in relapsed/refractory follicular lymphoma. We now report updated results of a single center, single-arm, Phase II trial of a single one-week …

The drug tositumomab and iodine I 131 tositumomab is used to treat cancer. It is a combination of tositumomab, a special type of antibody used to treat cancer, and …

Purpose: To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and overall survival and safety with the tositumomab and iodine-131 tositumomab ((131)I tositumomab) therapeutic regimen in patients with indolent, follicular large-cell, or transformed B-cell lymphoma, progressive …

Tositumomab is a murine IgG2a monoclonal antibody that selectively binds to CD20 on the surface of normal and malignant B cells. It can be labeled with iodine-131 to yield 131 I-labeled ...

46 Iodine I 131 Tositumomab 47 Iodine I 131 Tositumomab is a radio -iodinated derivat ive of Tositumomab 48 that has been covalently linked to Iodine-131. Unbound radio-iodine and 49 other reactants have been removed by chromatographic purification steps. 50 Iodine I 131 Tositumomab is supplied as a sterile, clear, preservative -free

Long-term, 5 patients developed elevated thyroid-stimulating hormone levels, 5 were diagnosed with myelodysplasia and 3 with solid tumors. A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL. (Blood. …

Tositumomab and iodine I 131 tositumomab (Bexxar® Therapeutic Regimen) has been found effective in relapsed/refractory follicular lymphoma. We now report updated results of a single center, single-arm, Phase II trial of a single one-week course of this treatment for 76 previously untreated, stage III and IV, follicular lymphoma …

STANFORD, California-Seventy percent of low-grade and transformed low-grade non-Hodgkin's lymphoma (NHL) patients respond to the drug iodine I 131 tositumomab (Bexxar) even though progressing after rituximab (Rituxan). A study of 40 patients who had previously failed to respond or progressed on rituximab, also showed that 40% had a …

The drug tositumomab and iodine I 131 tositumomab is used to treat cancer. It is a combination of tositumomab, a special type of antibody used to treat cancer, and iodine I 131, a radioactive element that has been shown to be effective against cancer. This drug is given intravenously (IV). Allergic reactions

For the dosimetric step, 450 mg of tositumomab in 50 mL of 0.9% sodium chloride is infused intravenously over 60 minutes. This is followed by 35 mg 5 mCi (185 MBq) of iodine 131 tositumomab in 30 mL of 0.9% sodium chloride over 20 minutes. Total body gamma camera counts and whole body images are obtained at 1 hour and before urination.

Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab. Authors: Sandra J. Horning, Anas …

Iodine I 131/ tositumomab is used for: Treating certain forms of non-Hodgkin lymphoma in patients who have not responded to other therapy. Iodine I 131/tositumomab is a …

This study demonstrated that the radiolabeled anti-CD20 monoclonal antibody therapy tositumomab and iodine I-131 tositumomab, followed by chemotherapy, is a potential …

Iodine I 131 tositumomab is a radiolabeled monoclonal antibody that attaches to a target marker on NHL cells. As a result, an immune response occurs and the antibody delivers a lethal dose of iodine 131 radiation to the tumor cells. Before embarking on the study, Dr. Leonard and other researchers knew that iodine I 131 tositumomab was able to ...

Tositumomab I 131. The Bexxar (tositumomab and iodine plus 131I-tositumomab) regimen consists of the sequential administration of a dose of the unlabeled murine Mab tositumomab to optimize biodistribution and increase tumor localization443,444 of the 131I-tositumomab that is administered thereafter.

Bexxar is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with CD20­-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed after treatment with rituximab. Bexxar is also referred to by its drug name, tositumomab and iodine I 131 tositumomab.

Tositumomab and iodine I 131 tositumomab should not be administered to patients with greater than 25% lymphoma marrow involvement, platelet count less than 100,000 cells/mm(3), or neutrophil count less than 1500 cells/mm(3). The tositumomab and iodine I 131 tositumomab therapeutic regimen is supplied only to certified healthcare …

Purpose: To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) and to compare its efficacy to the patients' last qualifying …

Tositumomab is a murine IgG2a monoclonal antibody that selectively binds to CD20 on the surface of normal and malignant B …

131I-Tositumomab (131I-B1 MAb) is a conjugation of 131I with a murine anti-CD20 monoclonal antibody (MAb) that can be used for both imaging and therapy of lymphoid malignancies (1-8). It was …

Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen.

Iodine I 131 tositumomab is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen, which is found specifically on B Iodine I 131 tositumomab - AdisInsight Either you have JavaScript disabled or your browser does not support Javascript .

Summary. Tositumomab is a monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. Generic Name. Tositumomab. DrugBank Accession Number. DB00081. Background. Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 …